c-MYC and SIRT1 locked in a vicious cycle
c-MYC and SIRT1 locked in a vicious cycle |
|
https://doi.org/10.18632/oncotarget.440
Antje Menssen,
and Heiko Hermeking
|
| 112-113 |
Modulating Mesothelin Shedding to Improve Therapy
Modulating Mesothelin Shedding to Improve Therapy |
|
https://doi.org/10.18632/oncotarget.445
Ira Pastan,
and Yujian Zhang
|
| 114-115 |
Bryostatin analog: improving on Nature’s design
Bryostatin analog: improving on Nature’s design |
|
https://doi.org/10.18632/oncotarget.460
Dale Boger
|
| 116-117 |
Targeting Mnks for Cancer Therapy
Targeting Mnks for Cancer Therapy |
|
https://doi.org/10.18632/oncotarget.453
Jinqiang Hou,
Frankie Kam,
Christopher G Proud,
and Shudong Wang
|
| 118-131 |
Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63.
Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63. |
|
https://doi.org/10.18632/oncotarget.447
Elena Martynova,
Silvia Pozzi,
Valentina Basile,
Diletta Dolfini,
Federico Zambelli,
Carol Imbriano,
Giulio Pavesi,
and Roberto Mantovani
|
| 132-143 |
Ras inhibition by FTS attenuates brain tumor growth in mice directly and by enhancing reactivity of cytotoxic lymphocytes
Ras inhibition by FTS attenuates brain tumor growth in mice directly and by enhancing reactivity of cytotoxic lymphocytes |
|
https://doi.org/10.18632/oncotarget.420
Elizabeta Aizman,
Adi Mor,
Ayelet Levy,
Jacob George,
and Yoel Kloog
|
| 144-157 |
Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice
Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice |
|
https://doi.org/10.18632/oncotarget.442
Ke Guo,
Jing Ping Tang,
Jie Li,
Cheng Peow Tan,
Abdul Qader O. Al-Aidaroos,
Cheng William Hong,
Leyon Varghese,
Zhi Wei Feng,
Jung Eun Park,
Jian Biao Zhou,
Wee Joo Chng,
and Qi Zeng
|
| 158-171 |
Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1
Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1 |
|
https://doi.org/10.18632/oncotarget.454
Julie S. Barber-Rotenberg,
Saravana P. Selvanathan,
Yali Kong,
Hayriye V. Erkizan,
Tara M. Snyder,
S. Peter Hong,
Christina L. Kobs,
Natalie L. South,
Steven Summer,
Philip J. Monroe,
Maksymilian Chruszcz,
Veselin Dobrev,
Perrer N. Tosso,
Lauren J. Scher,
Wladek Minor,
Milton L. Brown,
Steven J. Metallo,
Aykut Üren,
and Jeffrey A. Toretsky
|
| 172-182 |
Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor
Inhibition of p53 expression modifies the specificity of chromatin binding by the androgen receptor |
|
https://doi.org/10.18632/oncotarget.449
Natalya V. Guseva,
Oskar W. Rokhlin,
Thomas B. Bair,
Rebecca B. Glover,
and Michael B. Cohen
|
| 183-194 |
MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia
MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia |
|
https://doi.org/10.18632/oncotarget.448
Carlo Maria Croce,
Rosa Visone,
Angelo Veronese,
and Veronica Balatti
|
| 195-202 |
Novel targeted therapies for mantle cell lymphoma
Novel targeted therapies for mantle cell lymphoma |
|
https://doi.org/10.18632/oncotarget.426
Lapo Alinari,
Beth Christian,
and Robert Baiocchi
|
| 203-211 |
A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers
A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers |
|
https://doi.org/10.18632/oncotarget.450
Anita Lal,
Rebecca Panos,
Mira Marjanovic,
Michael Walker,
Eloisa Fuentes,
Daniel S. Kapp,
W David Henner,
Ljubomir J. Buturovic,
and Meredith Halks-Miller
|
| 212-223 |
